BCR::ABL1 tyrosine kinase inhibitors (TKIs) such as imatinib, have revolutionized the treatment of CML such that patients diagnosed and treated during chronic phase CML (CP-CML) are expected to have an excellent clinical response and normal life expectancy [2]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.